Received Feb 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | — |
rash; This is a spontaneous report received from a Consumer or other non HCP. A 42-year-old male patient received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), on 08Feb2025 at 07:00 as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Herpes" (unspecified if ongoing); "Drug allergy" (unspecified if ongoing), notes: Name of Drug as Reported: No. The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, SINGLE; MANUFACTURER UNKNOWN), for Covid-19 Immunization; Covid-19 vaccine (DOSE 2, SINGLE; MANUFACTURER UNKNOWN), for Covid-19 Immunization. The following information was reported: RASH (non-serious), outcome "recovering". Therapeutic measures were not taken as a result of rash. Additional information: The patient did not received any other vaccines on the same date as the vaccine(s) for which they were reporting. The patient did not received any other vaccines within 4 weeks PRIOR to the vaccine(s) for which they were reporting. The patient was not taking any other medications within 2 weeks of the event starting. Patient had recently seen a rash. The information on the batch/lot number for BNT162b2 omicron (kp.2) will be requested and submitted if and when received.
Medical History/Concurrent Conditions: Drug allergy (Name of Drug as Reported: No); Herpes virus infection